drugset / Trial / NCT03982693

Trial to Assess Chelation Therapy in Critical Limb Ischemia

NCT03982693

Phase 3 Active not recruiting 50 enrolled Mt. Sinai Medical Center, Miami
RandomizedParallel-groupTriple-blindTreatment

Summary

TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.

Timeline

Start
2019-03-19
Primary completion
2026-12
Completion
2027-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Edetate Calcium Disodium Unknown 3 g Other